The Business Research Company’s report on the Dermatomycoses Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
Which emerging drivers are set to accelerate the growth of the dermatomycoses market further?
The increasing prevalence of fungal infections is expected to propel the growth of the dermatomycoses market going forward. Fungal infections are conditions caused by fungi that infect the skin, nails, hair, or internal organs, resulting in different health issues. The excessive use of broad-spectrum antibiotics disrupts the natural microbiome, allowing fungi to thrive and cause infections. This imbalance weakens the body’s natural defense mechanisms, making individuals more vulnerable to opportunistic fungal infections. Dermatomycoses, caused by dermatophytes, yeasts, and molds, are responsible for fungal diseases, affecting various tissues and causing common superficial and systemic infections. For instance, in November 2023, according to the UK Health Security Agency, a UK-based public health agency responsible for protecting public health from infectious diseases, global estimates indicate an annual incidence of 6.5 million invasive fungal infections, resulting in approximately 3.8 million deaths, with 2.5 directly attributed to these infections. Therefore, the increasing prevalence of fungal infections drives the dermatomycoses market.
Rising Demand For Oral Drugs Fueling The Growth Of The Market Due To Their Convenience And Effectiveness
The rising demand for oral drugs is expected to propel the growth of the dermatomycoses market going forward. Oral drugs refer to medications that are taken by mouth in the form of tablets, capsules, or liquids and are absorbed through the digestive system. The demand for oral drugs is rising as they are a preferred choice over injections or other delivery methods due to their ease of convenience and effectiveness in treating a wide range of conditions. Dermatomycoses support the use of oral drugs by allowing systemic antifungal agents to penetrate infected skin, hair, or nails through blood circulation, ensuring deeper and prolonged treatment compared to topical applications. For instance, in October 2022, according to the Centers for Disease Control and Prevention, a US-based government administration, the dispensing of oral antivirals rose by 57%, increasing from 643 per 100,000 persons between April 24 and May 21, 2022, to 1,012 per 100,000 persons between July 31 and August 28, 2022. Therefore, the rising demand for oral drugs is driving the growth of the dermatomycoses market.
Access Your Free Sample of the Global Dermatomycoses Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=21934&type=smp
What are the key factors influencing the forecasted market size of the dermatomycoses industry?
The dermatomycoses market size has grown strongly in recent years. It will grow from $14.12 billion in 2024 to $14.95 billion in 2025 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to increasing advancements in antifungal therapies, increasing prevalence of fungal infections, rising awareness about skin health, increasing improved diagnostic techniques, and expansion of over-the-counter antifungal products.
The dermatomycoses market size is expected to see strong growth in the next few years. It will grow to $18.59 billion in 2029 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to the growing aging population, increasing incidence of drug-resistant fungal strains, rising demand for natural and organic antifungal products, increasing advancements in biotechnology and antifungal research, and expanding healthcare access in developing regions. Major trends in the forecast period include the development of novel antifungal drugs, advancement in rapid diagnostic techniques, integration of artificial intelligence in dermatology, advancement in nanotechnology-based antifungal treatments, and innovation in microbiome-based therapies.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=21934&type=smp
Who are the leading competitors in the dermatomycoses market?
Major companies operating in the dermatomycoses market are Pfizer Inc., Bayer AG, Saphnix Life Sciences, MITS Healthcare Private Limited, Weefsel Pharma, AdvaCare Pharma, Associated Biotech, Healthy Life Pharma Private Limited, Blueberry Therapeutics Ltd., Livealth Biopharma Pvt. Ltd., LGM Pharma, SiNi Pharma Pvt. Ltd., Joshi Agrochem Pharma Private Limited, Wellona Pharma, Abiba Pharmacia Pvt. Ltd., Vee Excel Drugs & Pharmaceuticals Pvt. Ltd., Femcorp Pharma, Lexicare Pharma Pvt. Ltd., Glamris Dermacare, Henin Lukinz
Which emerging trends are set to transform the dermatomycoses market landscape?
Major companies operating in the dermatomycoses market are focusing on investigational new drugs candidate to advance onychomycosis treatment and improve efficacy. An investigational new drug (IND) candidate is a pharmaceutical compound undergoing preclinical or clinical trials to evaluate its safety, efficacy, and potential for regulatory approval before becoming an approved treatment. For instance, in January 2024, Vanda Pharmaceuticals Inc., a US-based biopharmaceutical company received Investigational New Drug VTR-297 candidate for the treatment of onychomycosis approved by the US Food and Drug Administration (FDA), a US-based government agency. VTR-297 stands out as a topical antifungal candidate due to its histone deacetylase (HDAC) inhibitor properties, distinguishing it from traditional antifungal treatments. This works by targeting the root cause of fungal growth, demonstrating potent antifungal activity against dermatophytes and other fungi. This innovative mechanism of action has the potential to deliver faster and more effective treatment results while also reducing the likelihood of infection recurrence, addressing a significant unmet need in onychomycosis treatment.
How do different geographies compare in terms of market share and growth potential in the dermatomycoses market?
North America was the largest region in the dermatomycoses market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the dermatomycoses market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Order Your Report Now For Swift Delivery
https://www.thebusinessresearchcompany.com/report/dermatomycoses-global-market-report
Which major segments of the dermatomycoses market are experiencing the fastest growth?
The dermatomycoses market covered in this report is segmented –
1) By Drugs: Corticosteroids, Corticosteroid-Sparing Agents, Immunosuppressive, Immunomodulator, Antifungals, Other Drugs
2) By Route Of Administration: Oral, Parenteral, Topical, Other Routes Of Administration
3) By End-User: Hospitals, Specialty Clinics, Other End-Users
Subsegments:
1) By Corticosteroids: Topical Corticosteroids, Oral Corticosteroids, Injectable Corticosteroids
2) By Corticosteroid-Sparing Agents: Tacrolimus, Pimecrolimus
3) By Immunosuppressive: Methotrexate, Azathioprine, Cyclophosphamide
4) By Immunomodulator: Interferon-Gamma, Thalidomide
5) By Antifungals: Topical Antifungals, Oral Antifungals, Systemic Antifungals
6) By Other Drugs: Antihistamines, Antibacterial Agents
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21934
How is the dermatomycoses market defined, and what are its core characteristics?
Dermatomycoses are a group of fungal infections affecting the skin, hair, and nails, primarily caused by dermatophytes, yeasts, or molds. These infections often lead to itching, scaling, redness, and skin inflammation, impacting overall skin health. The main goal of treatment is to eliminate the fungal infection, alleviate symptoms, and prevent recurrence through the use of antifungal medications, maintaining proper hygiene, and following effective skin care practices.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
